



Review

The Role of Nutritional Status, Gastrointestinal Peptides and Endocannabinoids in the Prognosis and Treatment of Children with Cancer

Magdalena Schab ¹ and Szymon Skoczen ^{1,2,*}

¹ Department of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, 30-663 Krakow, Poland; magdalenaschab@interia.pl

² Department of Pediatric Oncology and Hematology, Faculty of Medicine, Jagiellonian University Medical College, 30-663 Krakow, Poland

* Correspondence: szymon.skoczen@uj.edu.pl

Abstract: Neoplastic diseases in children are the second most frequent cause of death among the young. It is estimated that 400,000 children worldwide will be diagnosed with cancer each year. The nutritional status at diagnosis is a prognostic indicator and influences the treatment tolerance. Both malnutrition and obesity increase the risk of mortality and complications during treatment. It is necessary to constantly search for new factors that impair the nutritional status. The endocannabinoid system (ECS) is a signaling system whose best-known function is regulating energy balance and food intake, but it also plays a role in pain control, embryogenesis, neurogenesis, learning, and the regulation of lipid and glucose metabolism. Its action is multidirectional, and its role is being discovered in an increasing number of diseases. In adults, cannabinoids have been shown to have anti-cancer properties against breast and pancreatic cancer, melanoma, lymphoma, and brain tumors. Data on the importance of both the endocannabinoid system and synthetic cannabinoids are lacking in children with cancer. This review highlights the role of nutritional status in the oncological treatment process, and describes the role of ECS and gastrointestinal peptides in regulating appetite. We also point to the need for research to evaluate the role of the endocannabinoid system in children with cancer, together with a prospective assessment of nutritional status during oncological treatment.

Keywords: cancer; children; nutritional status; endocannabinoid system; gastrointestinal peptides

Citation: Schab, M.; Skoczen, S. The Role of Nutritional Status, Gastrointestinal Peptides and Endocannabinoids in the Prognosis and Treatment of Children with Cancer. *Int. J. Mol. Sci.* **2022**, *23*, 5159. <https://doi.org/10.3390/ijms23095159>

Academic Editor: Stephen Bustin

Received: 15 March 2022

Accepted: 29 April 2022

Published: 5 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Childhood cancer is a rarely occurring disease. However, it is the second most frequent cause of death among children. It is estimated that each year cancer will be diagnosed in 400,000 children worldwide [1]. The cure rate in developed countries reaches 80%, while in low- and middle-income countries it is only 30% [2]. The most frequently diagnosed childhood cancers include acute lymphoblastic leukemia, brain tumors, lymphomas, and solid tumors such as Wilms and neuroblastoma [1,2]. Chemotherapy and radiotherapy are necessary treatments but have many side effects. One of the elements evaluated at diagnosis, influenced by both the disease and the treatment, is nutritional status [3]. It should be assessed regularly during therapy using anthropometric measurements, biochemical tests, a detailed nutritional interview, and appropriate scales [4]. It is important to choose adequately sensitive measurement methods since the body mass index (BMI) does not distinguish between muscle and fat mass and may distort the results, especially in children with oedemas and solid tumors when the real body weight is masked, respectively, by water and the mass of tumor [5]. In oncology, the gold standard in assessing body composition is dual-energy x-ray absorptiometry (DXA). However, it

has limited use in both low- and high-income countries [6]. A more affordable and cost-effective method of assessing nutritional status is the measurement of mid-upper arm circumference (MUAC), triceps skinfold thickness (TSFT), and arm muscle circumference (AMC), based on which it is possible to estimate the muscle and fat mass [4,6]. To assess body composition, the electrical bioimpedance analysis (BIA) can also be performed to evaluate the content of fat, lean tissue, and water [4]. Differences in sensitivity of detecting malnutrition with the use of individual measurement methods are presented by Lemos et al. [7], who assessed the nutritional status of 1154 children diagnosed with cancer based on BMI malnutrition was found in 10.8% at diagnosis, 27.3% based on TSFT, 24.5% based on MUAC, and 13.6% based on AMC.

Many factors contribute to the nutritional problems of children with cancer [8]. It is necessary to constantly search for new causes, one of which may be the altered functioning of the ECS. This system shows a multidirectional effect, and it has been best known for its regulation of energy balance. The role of the ECS is also described in an increasing number of diseases [9].

2. Nutritional Status in Children with Cancer

Nutritional status is the biochemical, structural, and functional state of the body resulting from the level of coverage of energy and nutrient requirements and the action of factors influencing absorption and metabolism [6]. In children diagnosed with cancer, the nutritional status is one of the prognostic values influencing treatment tolerance, quality of life, drug metabolism, and overall survival [4,10–12]. Malnutrition and overweight may occur at diagnosis or appear during and after oncological therapy but should not be treated as a normal condition at any stage of treatment. Despite the growing interest in this topic, malnutrition among cancer patients remains a serious problem, ranging between 40–90% in lower-middle-income countries and between 0–30% in high-income countries [3]. This value varies depending on the type and stage of cancer, phase of treatment, and assessment method [4]. In addition, patients with high-risk treatment protocols are more likely to be malnourished [13,14]. During oncological treatment, in some types of cancer, weight gain is also observed. According to Iniesta R. et al. [15], the prevalence of overnutrition ranged from 8% to 78%. It is believed that the first nutritional status assessment has to be performed at diagnosis and should be repeated regularly during treatment [4,13]. The most noticeable changes in the nutritional status occur in the first months after diagnosis [13,16]. In a prospective study, Paciarotti et al. [17] have shown that after the first three months of treatment, the content of adipose tissue in children with leukemia increased to 130% of the norm, while in children diagnosed with other cancer, it decreased from 78% at diagnosis to 70% of the norm after three months of treatment. Furthermore, weight loss of > 5% in the first 3 months of treatment and > 10% after 6 months were associated with poorer survival [12].

2.1. Nutritional Disorders in Children Diagnosed with Various Types of Cancer

2.1.1. Leukemia

Leukemia is the most common childhood cancer [1]. Studies show that obesity and undernutrition are associated with worse survival in children with acute myeloid leukemia (AML) [18]. Moreover, a higher BMI at diagnosis was associated with worse event-free survival (EFS), poorer overall survival (OS), and higher mortality in children with AML and those with acute lymphoblastic leukemia (ALL) [19–22]. On the other hand, Orgel E. et al. [23] showed that BMI at diagnosis wasn't as important as underweight and obesity occurring more than half of the time between induction and maintenance. Studies also indicate that obesity during induction increases the risk of persistent minimal residual disease (MRD) [24]. However, some studies do not confirm the relationship between BMI and EFS [25], MRD [26], and increased risk of recurrence [27,28]. Detailed studies are listed in Table 1.

It is also worth noting that children with leukemia are at risk of low muscle mass. Suzuki D et al. [29] have assessed the content of skeletal muscle in patients with ALL using CT imaging at the L3 level. Skeletal muscle loss was demonstrated in all patients after the induction, while sarcopenia developed in almost 30% of the study group [29].

Table 1. Characteristic of studies that assess nutritional status of children with leukemia.

Type of cancer	Patients (n)	Assesment Method	Nutritional Status at Diagnose	Outcome, Effect on Treatment	Age	Study Design	Year, Reference
AML	768	BMI ^a	10.9% underweight 14.8% patients were overweight	underweight patients had poorer survival (HR: 1.85; 95% confidence interval CI: 1.19–2.87; $p = 0.006$) and higher risk of treatment-related mortality (HR, 2.66; 95% CI: 1.38–5.11; $p = 0.003$) compared with middleweight patients; overweight patients had poorer survival (HR, 1.88; 95% CI: 1.25–2.83; $p = 0.002$), and higher risk of treatment-related mortality (HR: 3.49; 95% CI: 1.99–6.10; $p < 0.001$) and had higher leukocyte level ($p = 0.001$) compared with middleweight patients;	1–20	retrospective study	2005 [18]
AML, ALL	11602	BMI ^b	-	ALL—patients with BMI \geq 85th percentile had poorer EFS (RR: 1.35; 95% CI: 1.20, 1.51) and increased mortality (RR: 1.31; 95% CI: 1.09, 1.58) compared with patients with BMI $<$ 85th; AML—patients with BMI \geq 85th percentile had poorer EFS (RR: 1.36; 95% CI: 1.16, 1.60) and OS (and RR: 1.56; 95% CI: 1.32, 1.86) than patients with BMI $<$ 85th;	0–21	meta-analysis	2016 [19]
AML, ALL	181	BMI ^c	28.8% overweight/obese 71.2% non-overweight,	statistically significant association between mortality and obesity in unadjusted models (imputed: HR = 2.54, 95% CI = 1.15–5.60, $p = 0.021$; complete set: HR = 2.72, 95% CI = 1.26–5.91, $p = 0.011$) in overweight/obese patients \geq 10 years was observed trend towards increased risk of relapse (HR = 2.89, 95% CI = 0.89–9.36, $p \pm 0.08$) (age- and sex-adjusted analysis)	2–20	retrospective analysis	2018 [20]
AML, ALL	13,921	BMI	-	obesity at diagnosis was associated with increased risk of mortality (overall survival: HR = 1.30, 95% CI = 1.16–1.46, $p < 0.001$, and event-free survival: HR = 1.46, 95% CI = 1.29–1.64, $p < 0.001$)		systematic review	2016 [21]
ALL	4260	BMI ^d	8% obese 92% non obese	5-year event-free survival rate was higher in nonobese patients compared with obese 77% \pm 0.6% v 72% \pm 2.4% ($p = 0.02$); obesity patients had higher risk of events HR: 1.36 (95% CI, 1.04 to 1.77; $p = 0.021$) and relapses HR: 1.29 (95% CI, 1.02 to 1.56; $p = 0.04$); study cohort:	3–20	retrospective cohort study	2007 [22]

				obese patients ≥ 10 years had higher HR of events 1.5 (95% CI, 1.1 to 2.1; $p = 0.009$) and relapses 1.5 (95% CI, 1.2 to 2.1; $p = 0.013$) compared to non-obese patients; verification cohort: obese patients ≥ 10 years, had higher HR of events—1.42 (95% CI, 1.03 to 1.96; $p = 0.032$) and relapses 1.65 (95% CI, 1.13 to 2.41; $p = 0.009$);			
ALL	2008	BMI ^e	5.8% underweight, 13.9% obese	obesity and undernutrition at diagnosis were associated with poorer EFS (HR = 1.40; 95% CI, 1.13 to 1.73 and HR = 1.33; 95% CI, 0.97 to 1.83, respectively; global $p = 0.005$); obesity and undernutrition at diagnosis and for $\geq 50\%$ of the time between end of induction and start of maintenance were associated with poorer EFS (HR = 1.43; 95% CI, 1.04 to 1.96 and HR = 2.3; 95% CI, 1.46 to 3.63, respectively $p < 0.001$); obese patients were more likely to had hepatic and pancreatic toxicities (OR = 1.32; 95% CI, 1.15 to 1.51 and OR, 1.53; 95% CI, 1.22 to 1.92, respectively); underweight patients were more likely to had pulmonary toxicity and fungal infections (OR = 2.07; 95% CI, 1.31 to 3.29; $p = 0.003$ and OR = 2.24 95% CI, 1.51 to 3.32; $p = 0.001$, respectively);	1–20	retrospective cohort study	2014 [23]
ALL	198	BMI ^f	20.7% obese, 15.2% overweight, 64% patients were “lean”	obesity at diagnosis was associated with higher risk of MRD positive at the end of induction (OR = 2.57; 95% CI = 1.19 to 5.54; $p = 0.016$) compared with non-obese patients; Obesity and overweight were associated with poorer EFS irrespective of end-induction MRD ($p = 0.012$);	1–21	retrospective cohort study	2017 [24]
ALL	621	BMI ^g	16.4% underweight 10.3% at risk of overweight 8.9% overweight	there were no statistical differences between BMI groups in overall survival ($p = 0.533$), event-free survival ($p = 0.722$), and cumulative incidence of relapse ($p = 0.862$);	>1 year	retrospective study	2008 [25]
ALL	373	BMI ^h	7% underweight 12.1% overweight, 15.5% obese	no association between BMI and OR, EFS, cumulative incidence of relapse/ refractory disease (CIR) and MRD ($p > 0.05$);	>2	retrospective study	2017 [26]

ALL	172	BMI ^{hi}	<p>CDC: 14.9% underweight, 14.9% overweight, 11.8% obese</p> <p>WHO: 3.5% patients were assigned to the severely wasted or wasted group, 22.1% at risk of overweight, 7.0% overweight, 2.3% obese.</p>	no association between BMI determined by CDC or WHO criteria at diagnosis and DFS and OS;	0.5–15.5 (5)	observational retrospective study	2021 [28]
------------	-----	-------------------	--	---	-----------------	---	-----------

DFS—disease-free survival, **OS**—overall survival, **ALL**—acute lymphoblastic leukemia, **AML**—acute myeloid leukemia, **EFS**—event free survival, **BMI**—body mass index. **a**—BMI defined as: underweight BMI \leq 10th percentile, overweight BMI \geq 95th percentile, middleweight BMI 11th–94th percentiles, **b**—BMI defined as higher and lower: higher BMI defined as obese \geq 95% or overweight/obese (\geq 85%) or lower BMI defined as non-overweight/obese ($<$ 85%), **c**—BMI defined as overweight/obese \geq 85th percentile or non-overweight $<$ 85th percentile, **d**- obesity defined as a body mass index \geq 95th percentile for age and sex, **e**—underweight defined as BMI $<$ 5th percentiles, obese BMI \geq 95th percentiles, normal weight or overweight BMI 5–95th percentiles, **f**—obese defined as BMI \geq 95th percentile, overweight BMI 85–94th percentiles, “lean” BMI $<$ 85th percentiles, **g**—underweight defined as BMI \leq 10th percentile, normal weight—10th–85th percentiles, at risk of overweight BMI \geq 85th and $<$ 95th percentile, overweight BMI \geq 95th percentile, **h**—underweight defined as BMI $<$ 5th percentiles, normal weight BMI 5th–84.9th percentiles, overweight BMI \geq 85th and $<$ 95th percentile, obese BMI \geq 95th percentile, **i**—WHO criteria (Z-score), normal weight -1.9–0.9 z-score, wasted-severely wasted $<$ -2 z-score, risk of overweight 1–1.9 z-score, overweight-obesity \geq 2 z-score.

2.1.2. Solid Tumors

It is difficult to unequivocally define the prevalence of nutritional disorders in children with solid tumors due to the varied results of individual studies resulting from different methods and times of nutritional assessment, as well as a different selection of the study group [3]. It is believed that the risk of malnutrition in children with solid tumors is higher compared to other types of childhood cancers [13,30–33], although not all studies confirm this [34,35]. Studies indicate that both too high and low BMI is associated with worse OS [36,37], worse response to treatment [38], and a higher risk of toxicity [39] and complications [40]. On the other hand, Sharib JM. et al. [38] do not point to malnutrition as a factor associated with increased treatment toxicity. Tenardi R et al. [41] carried out a retrospective assessment of the nutritional status of children with Ewing sarcoma and osteosarcoma, where a high risk of experiencing extreme body changes was observed [41]. Burke [42] observed that the loss of > 10% of body weight was associated with an increased number of days of hospitalization [42]. Lifson L.F. et al. [43] have shown that malnutrition in children with Wilms' tumor reaches 66%, but no statistically significant relationship was found between nutritional status and survival [44,45]. In children with neuroblastoma, malnutrition is noticeable at diagnosis, and BMI decreases after 6 months of treatment, but no relationship has been found between BMI and survival [45]. In a prospective study by Avarnival et al. [46], it has been shown that the BMI of children with solid tumors decreased during the first 6 months of treatment and then gradually increased. It should be emphasized that the risk of malnutrition in children with solid tumors differs depending on the type of nutritional assessment method used. Children with solid tumors have a higher risk of malnutrition, regarding the MUAC, TSFT, and AMC indicators, compared to other methods [47]. This is caused by the tumor mass masking the real body weight, which impairs seemingly correct BMI measurements [47]. That is why it is so important to use measurements employing arm anthropometry, bioimpedance, or, if possible, DXA for these children. Furthermore, Joffe L. et al. [48] demonstrated by using single-slice T12-L1 images from routinely obtained chest CT scans that children with solid tumors lose skeletal muscle and fat in the early stages of therapy. Detailed studies are listed in Table 2.

Table 2. Characteristic of studies that assess the nutritional status of children with solid tumors.

Type of Cancer	Patients	Assessment Method	Nutritional Status at Diagnose	Outcome, Main Findings	Age (Years)	Study Design	Year, References
mixed	82	BMI ^a , MUAC, TSF, BIA	all patients: 13% undernutrition, 7% overweight, 15% obese, (BMI) solid tumors: 17% undernutrition, 8.5% obesity, (BMI)	undernutrition at diagnosis was associated with risk of event defined as relapse, death or becoming palliative (19.901; $p < 0.001$); overnutrition at diagnosis was not associated with risk o event ($p = 0.03$) patients with solid tumors had the highest prevalence of undernutrition at diagnosis compared to haematological malignances and brain tumors ($p < 0.05$) (17% by BMI and 18% by TSF) after 3 first months of treatment BMI ($p < 0.001$) and FM (BIA) ($p < 0.05$) increased, whilst FFM (BIA) ($p < 0.05$) significantly decreased during this time	<18	prospective cohort study	2019 [13]
solid tumors, hematological malignances	74	weight, height, BMI, MUAC, TSF, SSF, dietary intake	patients with solid tumors: 29.7% severely underweight, 10.8% stunted, 8.1% lean, and 45.9% wasted	high-treatment risk was associated with undernutrition during the first three months of treatment [$p = 0.04$; 95% CI (-16.8 to (-0.4)] patients with solid tumors had a significantly lower mean BMI ($p < 0.05$), TSF ($p < 0.01$), SSF ($p < 0.01$), and sums of TSF and SSF ($p < 0.01$) compared with patients with hematological malignancies hematological malignances patients had higher intake of energy, protein, carbohydrate, vitamin A, and niacin than children with solid tumors ($p < 0.05$) children with solid tumors had more eating problems (loss of appetite, nausea, and vomiting) than children with hematological malignances ($p < 0.05$)	3–15	cross-sectional study	2012 [30]
solid tumors, hematological malignances	74	BMI ^b , MUAC, TSFT, STRONGkid, PYMS	all patients: 12.3% undernutrition, 6.8% overnutrition solid tumors: 6.7% in the overall study population and 9.1% in patients with solid tumors;	no statistical differences between prevalence of undernutrition in solid tumor patients at baseline (16.7%) and hematologic malignances (10,9%) ($p = 0.869$) after 6 months of treatment, the prevalence of undernutrition decreased to 6.7% in the overall study population and 9.1% in patients with solid tumors;	1–18	prospective observational cohort study	2019 [31]

			16.7% undernutrition, 5.6% overnutrition	STRONGkids and PYMS revealed a high risk for malnutrition at diagnosis in 30.4% and 39.4% of patients with hematologic malignancies, and in 22.2% and 27.8% of patients with solid tumors, respectively			
mixed	366	BMI ^c , MUAC	BMI at diagnosis: 15% undernutrition, no significant difference in the 10-year overall survival by the malnutrition 18% overweight MUAC at diagnosis: 23% undernutrition, 6% overweight	in children with solid tumors MUAC identified more undernourished patients (23%) compared with BMI (15%), while BMI identified more overweight children with solid tumors (18%) compared to MUAC (6%) ($p = 0.001$) measured by BMI ($p = 0.1507$) or MUAC ($p = 0.8135$) the highest prevalence of undernutrition measuring by MUAC was in the solid tumor group (23%) compared with hematological and CNS cancers (11.5%, 8.6%, respectively) the highest prevalence of undernutrition measuring by BMI was in the CNS tumor group (20.7%) compared with solid tumor and CNS cancers (15%, 8.2%, respectively)	3 months– 18 years	retrospective cross-sectional study	2021 [32]
solid tumors, hematological malignances	127	BMI ^d , MUAC, TSFT, AMC	solid tumors group: undernourished was 29.4% by BMI, 45.6% by TSFT, 44.1% by MUAC, 33.8% by AMC	Patients with solid tumors had higher prevalence of malnutrition compared with hematological patients group, measured by BMI-z-score (29.4% v 6.8%, $p < 0.05$), MUAC (44.1% v 25.4%, $p < 0.05$), AMC (33.8% v 10.2%, $p < 0.05$) Higher percentages of deficits were shown by TSFT and MUAC than by z-score/BMI	1.08–24.58	prospective study	2005 [33]
solid tumors, hematological malignances	1154	TSFT, MUAC, AMC, BMI ^e , percentage weight loss	10.85% < adequate BMI, 20% > adequate BMI	no significant difference in the prevalence of malnutrition was observed between patients with solid tumors and hematological malignances in solid tumor group MUAC, TSFT identified more malnourished children compared with BMI and AMC (25.78%, 26.38% v 12.2%, 14.33%)	0–19	transversal observational study	2014 [34]
Ewing sarcoma	50	BMI ^f	16% underweight, 20% obese	abnormal BMI (underweight and obese) associated with poorer histologic response to treatment compared with patients with normal BMI (OR = 4.64, 95% CI 1.12–19.14 $p = 0.034$) and worse OS (HR = 3.46, 95% CI 1.19–9.99 $p = 0.022$) abnormal BMI not statistically significant associated with EFS	9.7–20.1	retrospective study	2015 [37]

Ewing sarcoma	142	BMI	-	BMI not associated with TRT	<21	retrospective study	2012 [38]
osteosarcoma	498	BMI ^g	14.7% low BMI, 8.6% high BMI	patients with high BMI had increased risk of arterial thrombosis (OR = 9.4, $p = 0.03$) patients with low BMI had increased risk of wound infection or slough (OR = 2.0, $p = 0.07$)	3.7–30	retrospective study	2011 [40]
osteosarcoma	710	BMI ^f	10.4% low BMI, 26.6% high BMI	high BMI associated with renal toxicity in course 2 of therapy (OR = 2.7, 95% CI 1.2–6.4, $p = 0.01$), poorer OAS at 5 years compared to patients with normal BMI - 69.7% vs. 80.5% (HR = 1.6, 95% CI 1.1–2.2, $p = 0.005$) and worse EFS at 3 years 66.2% vs. 75.5% (HR = 1.3 95% CI 0.9–1.8, $p = 0.05$)	2–20	retrospective study	2013 [39]
osteosarcoma, Ewing sarcoma	139	BMI ^h	at diagnosis: Ewing sarcoma 12.9% underweight, 8.1% overweight, 3.2% obese osteosarcoma 7.8% underweight, 10.4% overweight, 11.7% obese	patients with Ewing sarcoma or osteosarcoma are at a high risk of malnutrition, including extreme changes in body weight during therapy nutritional status not associated with outcome	1–27	retrospective study	2012 [41]
rhabdomyosarcoma	468	BMI ^h	9.83% underweight, 12.82% overweight, 11.54% obese	lost weight more than 10% from baseline associated with increased toxicities and increased number of days hospitalized when compared with patients who lost no more than 5% from baseline (OR = 1.24, 95% CI 1.00 – 1.54 $p = 0.0463$) BMI not associated with infection rate	2–20	retrospective study	2013 [42]
Wilms' tumor	76	weight, height, MUAC, TSFT, BMI ⁱ	BMI: 17.33% underweight mild, 6.67% underweight moderate, 5.33% underweight severe	malnutrition was not associated with poor outcome stage of disease was not significantly associated with nutritional status	0.9–12.4	prospective study	2016 [43]
Wilms' tumor	1532	weight-for-age ^j , BMI ^k	<2 years old ($n = 493$)	no association between weight-for-age or BMI-for-age and EFS ($p = 0.28$)	<2 years, >2 years	retrospective study	2009 [44]

			15.8% low WFA, 15.2% high WFA ≥2 years old (<i>n</i> = 1039) 15% low BMI, 13% high BMI					
Neuroblastoma	154	BMI ^k	24.0% underweight, 11.6% overweight	no statistically significant association between BMI and OS (<i>p</i> > 0,05) after 6 months of treatment, the BMI decreased in all children except patients with 4s disease (<i>p</i> < 0.01) and increase from baseline by 24 months (<i>p</i> = 0.007)	0–10.6	retrospective study	2015 [45]	
Mixed	139	BMI ^l	28% undernourished	patients with solid tumors, AML/CML, and CNS tumors were more likely to be malnourished compared to patients with ALL or lymphomas (RR 2.3; 95% CI, 1.3–3.9; <i>p</i> < 0.001)	2–16	retrospective study	2019 [46]	
Mixed	100	BMI ^d , MUAC, TSFT, AMC, albumin level	Malnourished was 37% of children by weight for age, 20% by height for age, 33% by BMI, 50% by TSFT, 39% by MUAC, 42% by AMC, 28% by albumin level	the overall prevalence of malnutrition was higher using arm anthropometry like MUAC and TSFT compared to measurement parameters like W/H z-scores or BMI	<18	prospective study	2008 [47]	
Type of cancer	Patients	Assesment Method	Nutritional Status at Diagnose	Outcome, Main Findings	Age (years)	Study Design	Year, References	
mixed	82	BMI ^a , MUAC, TSF, BIA	all patients: 13% undernutrition, 7% overweight, 15% obese, (BMI) solid tumors: 17% undernutrition, 8.5% obesity, (BMI)	undernutrition at diagnosis was associated with risk of event defined as relapse, death or becoming palliative (19.901; <i>p</i> < 0.001); overnutrition at diagnosis was not associated with risk o event (<i>p</i> = 0.03) patients with solid tumors had the highest prevalence of undernutrition at diagnosis compared to haematological malignances and brain tumors (<i>p</i> < 0.05) (17% by BMI and 18% by TSF)	< 18	prospective cohort study	2019 [13]	

				after 3 first months of treatment BMI ($p < 0.001$) and FM (BIA) ($p < 0.05$) increased, whilst FFM (BIA) ($p < 0.05$) significantly decreased during this time			
				high-treatment risk was associated with undernutrition during the first three months of treatment [$p = 0.04$; 95% CI (-16.8 to (-0.4)]			
solid tumors, hematological malignances	74	weight, height, BMI, MUAC, TSF, SSF, dietary intake	patients with solid tumors: 29.7% severely underweight, 10.8% stunted, 8.1% lean, and 45.9% wasted	patients with solid tumors had a significantly lower mean BMI ($p < 0.05$), TSF ($p < 0.01$), SSF ($p < 0.01$), and sums of TSF and SSF ($p < 0.01$) compared with patients with hematological malignancies hematological malignances patients had higher intake of energy, protein, carbohydrate, vitamin A, and niacin than children with solid tumors ($p < 0.05$) children with solid tumors had more eating problems (loss of appetite, nausea, and vomiting) than children with hematological malignances ($p < 0.05$)	3–15	cross-sectional study	2012 [30]
solid tumors, hematological malignances	74	BMI ^b , MUAC, TSFT, STRONGkid, PYMS	all patients: 12.3% undernutrition, 6.8% overnutrition solid tumors: 16.7% undernutrition, 5.6% overnutrition	no statistical differences between prevalence of undernutrition in solid tumor patients at baseline (16.7%) and hematologic malignances (10.9%) ($p = 0.869$); after 6 months of treatment, the prevalence of undernutrition decreased to 6.7% in the overall study population and to 9.1% in patients with solid tumors; STRONGkids and PYMS revealed a high risk for malnutrition at diagnosis in 30.4% and 39.4% of patients with hematologic malignances, and in 22.2% and 27.8% of patients with solid tumors, respectively;	1–18	prospective observational cohort study	2019 [31]
mixed	366	BMI ^c , MUAC	BMI at diagnosis: 15% undernutrition, 18% overweight MUAC at diagnosis: 23% undernutrition, no significant difference in the 10-year overall survival by the malnutrition 6% overweight	in children with solid tumors MUAC identified more undernourished patients (23%) compared with BMI (15%), while BMI identified more overweight children with solid tumors (18%) compared to MUAC (6%) ($p = 0.001$); measured by BMI ($p = 0.1507$) or MUAC ($p = 0.8135$);	3 months - 18 years	retrospective cross-sectional study	2021 [32]

the highest prevalence of undernutrition measuring by MUAC was in solid tumor group (23%) compared with hematological and CNS cancers (11,5%, 8,6%, respectively);
the highest prevalence of undernutrition measuring by BMI was in CNS tumor group (20,7%) compared with solid tumor and CNS cancers (15%, 8,2%, respectively);

solid tumors, hematological malignances	127	BMI ^d , MUAC, TSFT, AMC	solid tumors group: undernourished was 29,4% by BMI, 45,6% by TSFT, 44,1% by MUAC, 33,8% by AMC	Patients with solid tumors had higher prevalence of malnutrition compared with hematological patients group, measured by BMI- z-score (29,4% v 6,8%, $p < 0,05$), MUAC (44,1% v 25,4%, $p < 0,05$), AMC (33,8% v 10,2%, $p < 0,05$) Higher percentages of deficits were shown by TSFT and MUAC than by z-score/BMI	1.08–24.58	prospective study	2005 [33]
solid tumors, hematological malignances	1154	TSFT, MUAC, AMC, BMI ^e , percentage weight loss	10.85% < adequate BMI, 20% were > adequate BMI	no significant difference in the prevalence of malnutrition was observed between patients with solid tumors and hematological malignances; in solid tumor group MUAC, TSFT identified more malnourished children compared with BMI and AMC (25,78%, 26,38% v 12,2%, 14,33%); abnormal BMI (underweight and obese) associated with poorer histologic response to treatment compared with patients with normal BMI (OR= 4.33, 95% CI 1.12–19.14 $p = 0.034$) and worse OS (HR 2.76, 95% CI 1.19–9.99 $p = 0.022$);	0–19	transversal observational study	2014 [34]
Ewing sarcoma	50	BMI ^f	16% underweight, 20% obese	BMI not associated with EFS	9.7–20.1	retrospective study	2015 [37]
Ewing sarcoma	142	BMI	-	BMI not associated with TRT	< 21	retrospective study	2012 [38]
osteosarcoma	498	BMI ^g	14,7% low BMI, 8,6% high BMI	patients with high BMI had increased risk of arterial thrombosis (OR = 9.4, $p = 0.03$) patients with low BMI had wound infection or slough (OR = 2.0, $p = 0.07$)	3.7–30	retrospective study	2011 [40]
osteosarcoma	710	BMI ^h	10,4% low BMI, 26,6% high BMI	high BMI associated with renal toxicity in course 2 of therapy (OR = 2.7, 95% CI 1.2–6.4, $p = 0.01$), poorer OAS at 5 years compared to patients with	2–20	retrospective study	2013 [39]

				normal BMI - 69.7% vs 80.5% (HR = 1.6, 95% CI 1.1–2.2, $p = 0.005$) and worse EFS at 3 years 66.2% vs 75.5% (HR = 1.3 95% CI 0.9–1.8, $p = 0.05$)			
			at diagnosis:				
osteosarcoma, Ewing sarcoma	139	BMI ⁱ	Ewing sarcoma 12,9% underweight, 8,1% overweight, 3,2% obese	patients with Ewing sarcoma or osteosarcoma are at a high risk of malnutrition including extreme changes in body weight during therapy	1–27	retrospective study	2012 [41]
			osteosarcoma 7,8% underweight, 10,4% overweight, 11,7% obese	nutritional status not associated with outcome			
rhabdomyosarcoma	468	BMI ⁱ	9,83% underweight, 12,82% overweight, 11,54% obese	lost weight more than 10% from baseline associated with increased toxicities and increased number of days hospitalized when compared with patients who lost no more than 5% from baseline (OR = 1.24, $p = 0.0463$)	2–20	retrospective study	2013 [42]
				BMI not associated with infection rate			
Wilms' tumor	76	weight, height, MUAC, TSFT, BMI ^d	BMI: 17,33% underweight mild, 6,67% underweight moderate, 5,33% underweight severe <2 years old (n= 493)	malnutrition was not associated with poor outcome stage of disease was not significantly associated with on nutritional status	0.5–13	prospective study	2016 [43]
Wilms' tumor	1532	weight-for-age ^j , BMI ^j	15.8% low WFA, 15.2% high WFA ≥ 2 years old (n = 1039)	no association between weight-for-age or BMI-for-age and EFS ($p = 0,28$)	<2 years, >2 years	retrospective study	2009 [44]

			15% high BMI, 13% low BMI				
Neuroblastoma	154	BMI ^k	24.0% underweight, 11.6% overweight	no statistically significant association between BMI and OS ($p > 0,05$); after 6 months of treatment, the BMI decreased in all children except patients with 4s disease ($p < 0,01$) and increase from baseline by 24 months ($p = 0.007$);	0–10.6	retrospective study	2015 [45]
Mixed	139	BMI ^l	28% undernourished	patients with solid tumors, AML/CML, and CNS tumors were more likely to be malnourished compared to patients with ALL or lymphomas (RR 2.3; 95% CI, 1.3–3.9; $p < 0.001$);	2–16	retrospective cohort study	2019 [46]
Mixed	100	BMI ^d , MUAC, TSFT, AMC, albumin level	Malnourished was 37% of children by weight for age, 20% by height for age, 33% by BMI, 50% by TSFT, 39% by MUAC, 42% by AMC, 28% by albumin level	the overall prevalence of malnutrition was higher by arm anthropometry like MUAC and TSFT compared to measurements parameters like W/H z-scores or BMI;	<18	prospective study	2008 [47]

MUAC—mid-upper arm circumference, **TSF**—triceps skinfold, **SSF**—subscapular skinfold, **TSFT**—triceps skin fold thickness, **AMC**—arm muscle circumference, **PYMS**—Paediatric Yorkhill Malnutrition Score, **a**—undernutrition defined as BMI < 2.3rd centile; -2 SD, overweight as BMI \geq 85th < 95th centile; $\geq +1.05$ SD < 1.63 SD, obese as BMI \geq 95th centile; ≥ 1.63 SD, healthy weight BMI > 2.3rd to < 85th centile, **b**—BMI for age z-score: undernutrition z-score < -2 SD, normal nutritional status z-score ≥ -2 , ≤ 2 SD), overnutrition z-score > 2 SD, **c**—BMI for age z-score: undernutrition z-score < -2 , normal z-score ≥ -2 and $\leq +2$ for children 5 years old and younger; normal and risk of overweight z-score ≥ -2 and ≤ 1 for children over 5 years old, overweight z-score > +2 for children 5 years old and under, overweight, obesity and severe obesity z-score > +1 for children over 5 years old, **d**—BMI defined as WHO criteria z-score: normal weight ≥ -2 SD and < 1 SD, risk of overweight ≥ 1 SD and < 2 SD, overweight-obesity ≥ 2 SD, wasted-severely wasted < -2 SD, **e**—BMI defined as below adequate z-score < -2 SD, adequate z-score ≥ -2 SD and $\leq +1$ SD, above adequate z-score > +1 SD, **f**—BMI defined as low < 5th percentile, normal 5–85th percentile, overweight 85–95th percentile, obese > 95th percentile, **g**—low BMI defined as ≤ 10 th percentile, middle BMI 11th–94th percentile, high BMI ≥ 95 th percentile, **h**—adequately nourished defined as BMI ≥ 5 th to < 85th percentiles, underweight < 5th percentile, overweight > 85–95th percentile, obese > 95th percentile, **i**—underweight mild defined as BMI < -1 SD, underweight moderate BMI < -2 SD, underweight severe < -3 SD, **j**—< 2 years old: low Weight For Age (WFA) index < 10th percentile, high WFA > 90th percentile, ≥ 2 years old low BMI defined < 10th percentile, high BMI > 90th percentile, **k**—underweight defined as BMI < 15th percentiles, normal weight 15th–85th percentiles, overweight > 85th percentile, **l**—ISO-BMI, underweight defined as < 17 kg/m², healthy weight 17–24.9 kg/m², overweight 25–29.9 kg/m², obese ≥ 30 kg/m².

2.1.3. Central Nervous System (CNS) Tumors

Brain tumors are the second most common cancer in children after leukemia [1]. Tsutsumi et al. [49] have estimated that at diagnosis, 6.7% of children with CNS tumors were malnourished, while 23.3% were overweight. Iniesta R. et al. [13] confirm that patients with brain tumors had the highest risk of being overweight and obese compared to other types of cancer. In a prospective study, Brinksma A. et al. [16] have shown that in the first three months of treatment, most children with brain tumors increased the rate of WFA, BMI, and had a higher content of adipose tissue and lower lean body mass compared to children with solid tumors and hematological neoplasms. Musiol K. et al. [50] observed that in children with brain tumors, BMI was the lowest during the maintenance and was significantly different compared to the control group. After the end of treatment, BMI increased significantly [50].

2.2. Bone Health in Children with Cancer

The effect of treatment on the bone mineral content is also a very important issue because 40% of bone mass is formed in childhood [51]. Children treated for cancer show worse bone formation and higher bone resorption [52]. Added to the causes of bone structure disorders should be anti-cancer drugs like methotrexate, ifosfamide, cyclosporine, doxorubicin, cisplatin, and glucocorticosteroids, as well as radiotherapy, bone marrow transplantation, and decreased physical activity [52]. Studies show that children during treatment and cancer survivors have a significantly poorer bone mineral density (BMD) and a higher risk of osteoporosis, osteopenia, and fractures (Table 3).

Table 3. Characteristic of studies that assess bone health of children with cancer and survivors.

Cancer Type	Patients (n)/Control Group (n)	Assessment Method	Main Findings	Year, References
ALL	28/28	lumbar and total areal BMD, %FM, DXA, physical activity (accelerometer and questionnaire)	lumbar BMDvol in ALL survivors was significantly lower than in controls ($p < 0.01$); weekly activity score (by questionnaire) was significantly lower in the ALL group than in the control group ($p < 0.05$); male gender, low activity levels, intravenous high dose of methotrexate were associated with low lumbar BMDvol;	2002 [53]
ALL and solid tumors	28 (10 with ALL, 18 with solid tumors)	lumbar spine and femoral neck BMD, DXA, biochemical tests	femoral BMD and apparent volumetric density were decreased 1 year after diagnosis ($p < 0.01$); the markers of bone formation-PICP and OC were significantly decreased at diagnosis, and by the end of the study were normalized; marker of bone resorption (type I collagen carboxyl-terminal telopeptide) was significantly increased at the end of the study; levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, IGF-binding protein-3 were significantly decreased during the study;	1999 [54]
ALL	103	DXA, BMD	33% of patients had low BMD, and 4.9% of patients had osteoporosis;	2017 [55]
ALL	122	incidence of fractures, ON, bone pain	the relative rate of fractures was 2.03 (95% confidence interval 1.15–3.57), with greatest rates in children <5 years; the 5-year incidence of fractures, ON, and isolated bone pain was 13.5%, 12.1%, and 12.3%, respectively;	2007 [56]
ALL	155	BMD, lateral thoracolumbar spine radiographs, incident vertebral fractures	16% of children with ALL developed incident vertebral fractures 12 months after the initiation of therapy; no association between glucocorticoid or methotrexate dose and incident vertebral fracture;	2012 [57]
ALL	186	BMD, lateral thoracolumbar spine radiograph, bone age	children with grade 1 or higher vertebral compression had lower lumbar spine areal BMD Z-scores compared with children without ($p < 0.001$); lumbar spine BMD and back pain were associated with increased odds of fracture;	2009 [58]

ALL	124	DXA	at diagnosis: 30% had osteopenia, 11% had osteoporosis; during therapy-39.5% had osteopenia, 8% had osteoporosis; 18.5% patients developed fractures; predictors of fracture: dexamethasone therapy ($p = 0.01$), lower LS-BMD ($p = 0.01$);	2011 [59]
ALL, lymphoma	ALL-22 lymphoma-4	DXA	BMC and areal BMD were significantly lower than in healthy controls; no association between BMT and whole-body bone mass;	2000 [60]
osteosarcoma, Ewing's sarcoma	Ewing's sarcoma-18 osteosarcoma-25	DXA, BMD, fracture rate	58% had BMD reduction; 16% had fractures;	2012 [61]
osteosarcoma	40/55	DXA	47.5% had osteoporosis, 30.0% had osteopenia; risk factor of osteoporosis: young age at diagnosis, male sex, low lean mass;	2013 [62]
adult survivors of childhood brain tumors	74	DXA, biochemical tests	BMD was decreased in all measurement sites; male sex was associated with low BMD ($p < 0.05$); FSH and LH were negatively associated with BMD in women ($p < 0.05$);	2018 [63]
high-risk neuroblastoma	21/20	BMD, DXA, spinal magnetic resonance imaging	86% survivors had at least one skeletal adverse event; 38% had a severe complication;	2017 [64]
ALL	39	DXA, BMD	23.1% had osteopenia and 7.7% had osteoporosis;	2019 [65]
ALL	122		18% of survivors displayed osteopathologies ; 77% had impaired bone health (at least one pathological screening parameter); 15% had vitamin D deficiency;	2020 [66]
osteosarcoma	9/8	DXA, BMD of the lumbar spine and femur neck	44% had decreased lumbar spine BMD ($p = 0.024$); 78% had decreased femur neck BMD ($p = 0.023$);	2015 [67]
osteosarcoma	48 long term survivors > 10 years	BMD of the lumbar spine and proximal femur, DXA, biochemical tests	association between C-telopeptides with the BMD ($p = 0.04$)	2003 [68]

BMD—bone mineral density, **DXA**—dual-energy x-ray absorptiometry, **ALL**—acute lymphoblastic leukemia, **BMDvol**—volumetric bone mineral density, **ON**—osteonecrosis, **BMT**—bone marrow transplantation, **OC**—osteocalcin, **PICP**—type I collagen carboxylterminal propeptid.

Children with cancer have a higher risk of developing nutritional disorders than healthy children. Children with solid tumors are believed to be at greater risk of malnutrition than children with leukemia, who are more likely to be overweight and obese. Both malnutrition and obesity have a negative impact on survival, the occurrence of treatment toxicity, and EFS. The nutritional status assessment should be carried out regularly during therapy, and the assessment methods should be adapted to the type of tumor and the child's age. During treatment, it is also necessary to remember and counteract the long-term effects of anti-cancer therapy, e.g., the occurrence of osteopenia and osteoporosis in cancer survivors, because this group has a significantly increased risk of their occurrence.

3. Regulation of Appetite in Children with Cancer

3.1. Appetite Regulation

The regulation of appetite in humans is a complex mechanism influenced by many factors [69]. In the CNS, the hypothalamus is a key area influencing the regulation of appetite [69]. The starvation center is in the lateral hypothalamic area (LHA), and the satiety center is in the ventromedial hypothalamus (VMH) [69,70]. They are influenced by neuropeptides and hormonal signals from tissues and organs [71]. The integration of circulating signals of hunger and satiety takes place in the arcuate nucleus (ARC), within which there are two opposing neuronal systems [71]. The first of them is the orexigenic system, which stimulates appetite through neuropeptide Y (NPY) and agouti-related peptide (AgRP) [72]. The second one is the anorexigenic system suppressing appetite through a proopiomelanocortin (POMC) and the amphetamine-regulated transcript (CART) [72]. Then, signals are transmitted to the paraventricular hypothalamic nucleus (PVN), where they are integrated and modified [73]. The neurons of PVN send axons that secrete corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and oxytocin (OXT) [73]. The arcuate nucleus also communicates with VMH, which secretes mainly anorexigenic brain-derived neurotrophic factor (BDNF) [73], and LHA, which secretes the appetite-stimulating peptides orexin-A (OxA), orexin-B (OxB), and melanin-concentrating hormone (MCH) [71].

Peripheral appetite regulators include gastrointestinal and adipose tissue hormones reaching the CNS via the bloodstream [70,74] but not all of them can cross the blood-brain barrier [75]. Gut peptides also affect the brain via vagal afferent fibers [71]. Leptin is a peptide produced mainly by white adipose tissue, and its concentration in the body positively correlates with the BMI and the amount of adipose tissue [76]. The action of leptin in the human body is multidirectional, but best known is its participation in the regulation of hunger and satiety, where it stimulates the POMC/CART system and inhibits the secretion of NPY [69,71]. Ghrelin, a gastrointestinal hormone produced in humans mainly in the stomach by type A enteroendocrine cells, has the opposite effect as leptin [77]. Stimulation of the starvation center is the main function of ghrelin, which negatively correlates with the BMI and concentration of leptin and insulin [70,74,78]. The lesser known functions of ghrelin are modulation of taste sensation, glucose metabolism, and gut motility [70]. Ghrelin level positively correlates with the severity of anorexia and cancer cachexia in adult patients [79–81]. Another important regulator is insulin, a long-term signal of satiety that can cross the blood-brain barrier [71]. Insulin stimulates leptin synthesis and inhibits NPY/AgRP neurons [69,71]. Glucagon-like peptide 1 (GLP-1) inhibits gastric emptying and reduces appetite, and stimulates the pancreas to secrete insulin [82]. This hormone has an important role in glucose metabolism [82]. Another peptide inhibiting food intake is peptide tyrosine-tyrosine (PYY), secreted in the distal intestine after a meal, especially after a protein-rich one [83]. Cholecystokinin (CCK) is synthesized mainly in the duodenum and jejunum, but also in the CNS [84]. It suppresses appetite and stimulates intestinal motility and secretion of insulin, glucagon, and pancreatic enzymes [85].

Moreover, genetic factors also play a role in regulating the level of intestinal hormones and thus the appetite. This was confirmed by Czogała et al. [86], who assessed the importance of FTO and PLAG1 gene expression in the context of gastrointestinal and

adipose tissue hormone levels. The results indicate that the level of FTO and PLAG1 expression positively correlated with the concentration of leptin in the blood serum and negatively with CCK and GLP-1, while the expression and methylation of FTO negatively correlated with the levels of resistin and visfatin [86].

3.2. The Causes of Appetite and Nutritional Status Disorders in Children with Cancer

There are many factors contributing to cancer malnutrition (Table 4), which in contrast to starvation-related malnutrition is not caused only by insufficient food intake [87,88].

Table 4. Causes of appetite loss in cancer patients [87–89].

Factors	Description
hormonal imbalance	gastrointestinal hormones
	adipose tissue hormones
	neurohormones
proinflammatory cytokines	IL-1
	IL-6
	TNF- α
	IFN- γ
substances secreted by tumor	PIF
	PMF
	LMF
metabolism changes	proteolysis \uparrow
	lipolysis \uparrow
	glycolysis \uparrow
side effects of treatment	taste and smell dysfunction
	nausea, vomiting
	impaired intestinal motility
	oral mucositis

IL-1—interleukin 1, IL-6—interleukin 6, INF- γ —interferon gamma, LMF—lipid mobilizing factor, PIF—protein inducing factor, TNF- α —tumor necrosis factor, PMF—protein mobilizing factor

During cancer treatment, the action of neurohormones, gastrointestinal, and adipose tissue hormones also may change [88]. Only a few studies have shown gastrointestinal peptide dysfunction in children with cancer, and most have been conducted in children with leukemia. Fayh et al. [90] carried out a systematic review, which showed a wide variation in results. Most of the included studies [90] looked at the concentration of leptin, but in only one research was a higher level of leptin observed in children with cancer [91], while the remaining studies found lower concentration or no difference compared with the control group [90]. Only two studies looked at ghrelin concentration, and one of them indicated lower ghrelin levels in children with cancer, which increased in later stages of treatment [91]. As the causes of the varied results, the authors indicate different types of cancers, treatments, and ages of children [90]. Agyrou et al. [92] (2019) presented an overview of research on ghrelin, leptin, and adiponectin levels in children with ALL. They noticed that in most studies, the leptin level was higher and the adiponectin level was lower at diagnosis [92]. Furthermore, Carvalho Gomes CC et al. [93] assessed the levels of appetite-regulating hormones in children with ALL during the induction at three-time points. Statistically significant changes have been observed in the level of ghrelin, which positively correlated with food consumption [93]. The concentration of leptin, insulin, and cortisol did not change significantly during the 28 days of the study [93]. Barbosa-Corte et al. [94] have shown that malnourished children with solid tumors and lymphomas have a lower leptin concentration than well-nourished children. Musial et al. [50] observed no statistically significant differences between leptin levels in children with CNS tumors and

the control group and no correlation between leptin concentration and BMI. Statistically, an insignificant lower leptin level at diagnosis was observed in patients with brain tumors compared to the control group (7.04 vs. 16.38 ng/mL) and malnourished children [50]. Changes in gastrointestinal peptides have also been indicated by Skoczerni et al. [95], who observed that the concentration of CCK, ghrelin, and GLP-1 and the expression of their genes were significantly lower before bone transplant compared to 6 months after transplantation. Moreover, the concentrations of peptides in the test group were significantly lower than in the control group of healthy children [95]. The authors indicate that it may be caused by damage to the gastrointestinal mucosa, and the measurement of the concentrations of selected peptides may be a marker of gastrointestinal regeneration [95].

Appetite is also altered by disturbed gastrointestinal tract motility, taste, and smell disturbances, occurring at 45–84% for taste and 5–60% regarding the smell of adult cancer patients [8]. Cancer patients also exhibit increased protein catabolism and lipolysis, as well as inhibition of lipoprotein lipase [8,87]. The deterioration of the body condition leads to the development of cachexia characterized by unintentional weight loss, including muscle and fat tissue, marked weakness, dysfunctional immunity, decreased intestinal peristalsis, and abnormal functioning of the heart and other key organs and systems of the body [89].

Appetite regulation in humans is very complex and involves both CNS centers and peripheral factors. During oncological treatment, the action of hunger and satiety centers is disturbed by the action of proinflammatory cytokines, substances secreted by cancer, and metabolic disorders. In children with cancer, changes in the level of gastrointestinal peptides such as CCK, ghrelin, leptin, and GLP-1 are also observed. However, the results of individual studies are contradictory, and this issue requires further research.

4. The Role of Endocannabinoids System in Childhood Cancer

4.1. Physiology of ECS

ECS is a system of endogenous cannabinoids, receptors, enzymes, and transport proteins, discovered in the 90s [9,96]. It is found in mammals, other vertebrates, and some invertebrates [9,97]. In humans, it is already present in the embryo, while cannabinoid receptors in the brain are detected in the 14th week of fetal life [98]. Moreover, blocking CB1 receptors in mice in the first 24 h of life inhibited the suckling of milk [99]. Added to the best known and first discovered ECS ligands should be included anandamide (AEA) and 2-arachidoyl glycerol (2-AG) [100,101]. Both endocannabinoids are formed “on-demand” [102]. They are lipid derivatives of arachidonic acid (AA) belonging to omega-6 polyunsaturated fatty acids [9]. The precursor of AEA is N-acylphosphatidylethanolamine (NAPE), from which in the brain, kidneys, liver, lungs, spleen, and heart, anandamide and phosphatidic acid are formed using N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) [9,97,103]. The 2-arachidonoyl glycerol is formed from diacylglycerol (DAG) using diacylglycerol lipase (DAGL) and phospholipase C [104–107]. Endocannabinoids have to leave the cell to fulfill their function, and due to their polar nature, the eCB membrane transporter must be involved. The termination of endocannabinoid signaling is intracellular [108]. AEA is mainly degraded by fatty acid amide hydrolase (FAAH) to ethanolamine and arachidonic acid, while 2-AG is hydrolyzed by monoacylglycerol lipase (MAGL) to arachidonic acid and glycerol [109]. It is worth noting that arachidonic acid formed due to hydrolysis is a substrate for the production of prostaglandins [9].

In the ECS, there are two main types of receptors—CB1 and CB2, which are G protein-coupled receptors (GPCRs) [96]. CB1 receptors are located primarily in the brain—most of them in the basal ganglia, cerebellum, hippocampus, and cortex [108]. They are also located in endocrine glands, thyroid and adrenal cells, ovaries, testes, uterus, and placenta, in the gastrointestinal tract, and in adipose tissue, where endocannabinoids activate lipoprotein lipase and fat deposition [110]. In addition, CB1 receptors are also found

in the vagus nerve endings [110]. CB2 receptors are located mainly in cells of the immune system—on the surface of B lymphocytes, macrophages, monocytes, and NK cells. Moreover, they are also in the spleen, tonsils, and hematopoietic cells [111], and in the CNS they are located mainly in microglia [92]. Anandamide has a high affinity for the CB1 receptor and low affinity for CB2, while 2-AG can bind to both receptors [96].

4.2. *The Role of the ECS in the Regulation of Appetite*

The ECS in the human body works in a multidirectional way, and its role is still being investigated [9]. The best-known function of ECS is the regulation of energy balance and food consumption [9]. Other known functions of the ECS include pain control, thermogenesis, sleep cycle regulation, embryogenesis, neurogenesis, learning, and memory, as well as regulation of lipid and glucose metabolism [9,109,111].

In the appetite control process, CB1 receptors in appetite-regulating regions of the hypothalamus are involved, as well as CB1 receptors located in the limbic system, digestive tract, and adipose tissue [109]. It is worth noting that by the presence of these receptors in the limbic system, ECS takes part in the hedonic evaluation of food [70]. The ECS also decreases gastric acid secretion and gastrointestinal motility [112]. A study on an animal model confirms the role of endocannabinoids in regulating the energy balance. Mice with knockout CB1 receptors had lower body weight, were resistant to hyperphagia [113], and were insensitive to the action of leptin [114]. Activation of the CB1 receptors in OUN leads to increasing motivation for palatable foods and increasing odor sensitivity, which leads to a reduction of satiety feeling and increased food intake (Figure 1) [115,116]. ECS also interacts with gastrointestinal peptides. Activation of the ECS leads to ghrelin secretion, which increases appetite (Figure 1) [102]. This is a two-way action because the ECS system stimulates the secretion of ghrelin in the digestive system, while ghrelin stimulates the synthesis of 2-AG [116]. Furthermore, in CB1 knockout mice, ghrelin didn't show an anorexigenic effect [117]. It has also been known that leptin levels negatively correlate with endocannabinoid concentration [110,118] (Figure 1). Activation of CB1 receptors also leads to an increase in insulin secretion, somatostatin, glucagon, and visfatin [110]. Furthermore, cholecystokinin reduces the expression of CB1 receptors [119].

A high-fat and high-calorie diet can also modulate the ECS. Tagliamonte et al. [120] have shown that overweight and obese people have lower plasma AEA levels after switching from the Western to the Mediterranean diet, possibly due to increased intake of polyunsaturated fatty acids and decreased consumption of saturated fatty acids. In another study, Tagliamonte et al. [121] have shown that fat and energy intake can influence the concentration of endocannabinoids, NAE, and NAPE.




Figure 1. The role of endocannabinoid system (ECS) and gastrointestinal peptides in the regulation of appetite.

4.3. The Role of ECS in Childhood Cancer

The potential role of ECS in the development and course of diseases is still being investigated. It is currently known that in children it plays a role in the pathogenesis of such diseases as immune thrombocytopenia, juvenile idiopathic arthritis, type 2 diabetes, inflammatory bowel disease, celiac disease, obesity, and inflammation of the nervous system [122]. There is no data in the literature on the role of ECS in oncological diseases in children. Most of the research is carried out among adults, where the anti-cancer properties of cannabinoids have been demonstrated in breast and pancreatic cancer, melanoma, lymphoma, and brain tumors [111]. Among children, there are single studies assessing the importance of the cannabinoid system and synthetic cannabinoids. Andradas [111] points out that most of the conducted studies concern acute lymphoblastic leukemia, which indicates that cannabinoids destroy cancer cells both in vivo and in vitro and that cannabinoids THC and CBD interact with vincristine, cytarabine, and doxorubicin in vitro [123,124]. It has also been shown that synthetic cannabinoids inhibit rhabdomyosarcoma growth [125] and reduce the viability and invasiveness of neuroblastoma cells [126]. Furthermore, synthetic cannabinoids induced cell cycle arrest of osteosarcoma cells [127]. In the case of brain tumors, it has been shown that in the group of children with low-grade gliomas, the level of CB1 expression was a predictor of spontaneous involution [128]. Study details are listed in Table 5.

The role of ECS in children's oncology is still little known. In vitro studies indicate the anti-cancer effects of cannabinoids on leukemia, neuroblastoma, rhabdomyosarcoma, and osteosarcoma cells. Furthermore, cannabinoids can enhance the toxic effects of drugs. Another interesting issue is the interaction of endocannabinoids with gastrointestinal peptides. Endocannabinoids correlate positively with ghrelin secretion and negatively with leptin secretion. This topic also requires future research, especially in children with cancer.

Table 5. Characteristic of studies that assess cannabinoid anti-cancer potential in children.

Type of Cancer	Cannabinoid/EC S Element	Details	Main Findings	Year, References
leukemia	CBD, CBG, THC	human cancer cell lines CEM (acute lymphocytic leukemia) and HL60 (promyelocytic leukemia)	combination of endocannabinoids (especially with CBD) has a greater anti-cancer response compared with the use of cannabinoids separately; combination of endocannabinoids worked synergistically with vincristine and cytarabine; greater induction apoptosis was observed when cannabinoids were used after anti-cancer drugs;	2017 [109]
leukemia	THC	leukemic cell lines CEM (lymphoblastic), HL60 (promyelocytic), and MOLT4 (lymphoblastic)	THC significantly strengthened the action of cytarabine, doxorubicin, and vincristine in reducing cell number and viability; THC makes leukemic cells more sensitive to the cytotoxic effects of chemotherapy;	2008 [110]
rhabdomyosarcoma	HU210, Met-F-AEA AM251, THC	Rh4, Rh28 (translocation positive rhabdomyosarcoma cells) RMS13, RD, and MRC-5 (lung fibroblast cells)	HU210, THC, and Met-F-AEA have proapoptotic effects on tposRMS cells through the CB1 receptor; HU210, THC, and Met-F-AEA reduce viability through up-regulation of transcription factor p8;	2009 [111]
neuroblastoma	CBD, THC	SK-N-SH	CBD and THC have antitumorigenic activity in vitro and decreased growth of tumors in vivo; CBD was more active than THC; CBD induces apoptosis and increases caspase-3 levels in the SK-N-SH neuroblastoma cell, and reduced the viability and invasiveness of tumor cells in vitro;	2016 [112]
neuroblastoma	AM404 (ECS modulator)	SK-N-SH	AM404 inhibits NFAT and NF- κ B transcriptional activity by CB1- and TRPV1-independent mechanism; AM404 inhibits MMP-1, -3, and -7 expression and cell migration ;	2015 [116]
osteosarcoma	WIN, ANA, MethANA, 3-MA	MG63, Saos-2	WIN decreased cell number and morphological alterations, with no association with induction of cell death; WIN induced G2/M cell cycle arrest;	2014 [113]
low-grade glioma	CB1 receptor	33 sample LGG	in LGG pediatric tumors which remained stable or underwent spontaneous involution observed high CNR1 expression at diagnosis	2016 [114]
leukemia	CP55940	Jurkat clone E6-1 (T-ALL), PBL	CP55940 induced production of ROS and apoptosis in Jurkat cells, but not in PBL; Mechanism of cell death in Jurkat is CBR-independent;	2020 [117]

CBD – Cannabidiol, **CBG** – cannabigerol, **THC** – Δ^9 -tetra- hydrocannabinol.

5. Conclusions

- both underweight and obesity in children with cancer are associated with adverse outcomes, poorer EFS and OS;
- children with cancer and cancer survivors are at risk of developing osteoporosis and osteopenia;
- the literature lacks studies prospectively assessing the nutritional status over the entire period of the oncological treatment as well as studies on the importance of gastrointestinal hormones and the endocannabinoid system in this group of patients;
- the current state of knowledge allows only to suspect the existence of a relationship between nutritional status, gastrointestinal peptides and endocannabinoids;
- this issue requires further research, and it is important not only due to the possible impact on the nutritional status but also due to the multidirectional action of the ECS, which may be important in future oncological therapies;

Author Contributions: Conceptualization, M.S., S.S.; writing—original draft preparation, M.S., S.S.; writing—review and editing, M.S., S.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

2-AG	2-arachidnoiloglycerol
AEA	anandamide
AgRP	and agouti-related peptide
ALL	acute lymphoblastic leukemia
AMC	arm muscle circumference
AML	acute myeloid leukemia
ARC	arcuate nucleus of the hypothalamus
BIA	bioelectrical impedance analysis
BMD	bone mineral density
BMDvol	volumetric bone mineral density
BMI	body mass index
BMT	bone marrow transplantation
CART	cocaine-amphetamine-regulated transcript
CBD	cannabidiol
CBG	cannabigerol
CCK	cholecystokinin
CI	confidence interval
CNS	central nervous system
CRH	corticoliberin
DAG	diacylglycerol
DAGL	diacylglycerol lipase
DXA	dual-energy x-ray absorptiometry
ECS	endocannabinoid system
EFS	event-free survival
FAAH	fatty acid amide hydrolase
GABA	gamma-aminobutyric acid
GLP-1	glucagon-like peptide 1
GPCRs	G protein-coupled receptors
IL-1 β	interleukin 1 β

IL-6	interleukin 6
IFN- γ	interferon gamma
LHA	lateral nuclei of the hypothalamus
LMF	lipid mobilizing factor
MAGL	monoacylglycerol lipase
MCH	melanin-concentrating hormone
MUAC	mid-upper arm circumference
NA	noradrenaline
NAPE	N-acyl phosphatidylethanolamine
NAPE-PLD	N-acyl phosphatidylethanolamine phospholipase D
NPY	neuropeptide Y
ON	osteonecrosis
OS	overall survival
PGE2	prostaglandin E2
PIF	proteolysis inducing factor
PMF	protein mobilizing factor
POMC	proopiomelanocortin
PVN	paraventricular nucleus
PYMS	Paediatric Yorkhill Malnutrition Score
PYY	peptide tyrosine-tyrosine
THC	Δ^9 -tetra- hydrocannabinol
TNF- α	tumor necrosis factor
TRH	thyrotropin releasing hormone
TSFT	triceps skinfold thickness
VMH	ventromedial hypothalamus
WFA	weight-for-age index

References

- World Health Organization. CureAll Framework: WHO Global Initiative for Childhood Cancer: Increasing Access, Advancing Quality, Saving Lives. License: CC BY-NC-SA 3.0 IGO. 2021. Available online: <https://apps.who.int/iris/handle/10665/347370>. <https://apps.who.int/iris/handle/10665/347370> (accessed on 11 January 2021).
- Lam, C.G.; Howard, S.C.; Bouffet, E.; Pritchard-Jones, K. Science and health for all children with cancer. *Science* **2019**, *363*, 1182–1186.
- Diakatou, V.; Vassilakou, T. Nutritional Status of Pediatric Cancer Patients at Diagnosis and Correlations with Treatment, Clinical Outcome and the Long-Term Growth and Health of Survivors. *Children* **2020**, *7*, 218.
- Viani, K.; Trehan, A.; Manzoli, B.; Schoeman, J. Assessment of nutritional status in children with cancer: A narrative review. *Pediatr. Blood Cancer* **2020**, *67*, e28211.
- Shah, p.; Jhaveri, U.; Idhate, T.B.; Dhingra, S.; Arolkar, P.; Arora, B. Nutritional status at presentation, comparison of assessment tools, and importance of arm anthropometry in children with cancer in India. *Indian J. Cancer* **2015**, *52*, 210–215.
- Barr, R.D.; Stevens, M.C.G. The influence of nutrition on clinical outcomes in children with cancer. *Pediatr. Blood Cancer* **2020**, *67*, e28117.
- Dos Maia Lemos, P.S.; Ceragioli Oliveira, F.L.; Monteiro-Caran, E.M. Nutritional Status at Diagnosis in Children with Cancer in Brazil. *Pediatr. Ther.* **2016**, *6*, 389–395.
- Co-Reyes, E.; Li, R.; Huh, W.; Chandra, J. Malnutrition and obesity in pediatric oncology patients: Causes, consequences, and interventions. *Pediatr. Blood Cancer* **2012**, *15*, 1160–1167.
- Lu, H.C.; Mackie, K. Review of the Endocannabinoid System. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* **2021**, *6*, 607–615.
- Rogers, P.C. Nutritional status as a prognostic indicator for pediatric malignancies. *J. Clin. Oncol.* **2014**, *32*, 1293–1294.
- Brinksma, A.; Huizinga, G.; Sulkers, E.; Kamps, W.; Roodbol, P.; Tissing, W. Malnutrition in childhood cancer patients: A review on its prevalence and possible causes. *Crit. Rev. Oncol. Hematol.* **2012**, *83*, 249–275.
- Triarico, S.; Rinninella, E.; Cintoni, M.; Capozza, M.A.; Mastrangelo, S.; Mele, M.C.; Ruggiero, A. Impact of malnutrition on survival and infections among pediatric patients with cancer: A retrospective study. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 1165–1175.
- Iniesta, R.R.; Paciarotti, I.; Davidson, I.; McKenzie, J.M.; Brougham, M.F.H.; Wilson, D.C. Nutritional status of children and adolescents with cancer in Scotland: A prospective cohort study. *Clin. Nutr. ESPEN* **2019**, *32*, 96–106.
- Pribnow, A.K.; Ortiz, R.; Báez, L.F.; Mendieta, L.; Luna-Fineman, S. Effects of Malnutrition on Treatment-Related Morbidity and Survival of Children with Cancer in Nicaragua. *Pediatr. Blood Cancer* **2017**, *64*, e26590.
- Iniesta, R.R.; Paciarotti, I.; Brougham, M.F.; McKenzie, J.M.; Wilson, D.C. Effects of pediatric cancer and its treatment on nutritional status: A systematic review. *Nutr. Rev.* **2015**, *73*, 276–295.

16. Brinksma, A.; Roodbol, P.F.; Sulkers, E.; Kamps, W.A.; de Bont, E.S.; Boot, A.M.; Burgerhof, J.G.; Tamminga, R.Y.; Tissing, W.J. Changes in nutritional status in childhood cancer patients: A prospective cohort study. *Clin. Nutr.* **2015**, *34*, 66–73.
17. Paciarotti, I.; McKenzie, J.M.; Davidson, I. Short term effects of childhood cancer and its treatments on nutritional status: A prospective cohort study. *EC Nutr.* **2015**, *3*, 528–540.
18. Lange, B.J.; Gerbing, R.B.; Feusner, J.; Skolnik, J.; Sacks, N.; Smith, F.O.; Alonzo, T.A. Mortality in overweight and underweight children with acute myeloid leukemia. *JAMA* **2005**, *12*, 203–211.
19. Orgel, E.; Genkinger, J.M.; Aggarwal, D.; Sung, L.; Nieder, M.; Ladas, E.J. Association of body mass index and survival in pediatric leukemia: A meta-analysis. *Am. J. Clin. Nutr.* **2016**, *103*, 808–817.
20. Saenz, A.M.; Stapleton, S.; Hernandez, R.G.; Hale, G.A.; Goldenberg, N.A.; Schwartz, S.; Amankwah, E.K. Body Mass Index at Pediatric Leukemia Diagnosis and the Risks of Relapse and Mortality: Findings from a Single Institution and Meta-Analysis. *J. Obes.* **2018**, *2018*, 1–8.
21. Amankwah, E.K.; Saenz, A.M.; Hale, G.A.; Brown, P.A. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: A systematic review and meta-analysis. *Leuk. Lymphoma* **2016**, *57*, 1140–1148.
22. Butturini, A.M.; Dorey, F.J.; Lange, B.J.; Henry, D.W.; Gaynon, P.S.; Fu, C.; Franklin, J.; Siegel, S.E.; Seibel, N.L.; Rogers, P.C.; et al. Obesity and Outcome in Pediatric Acute Lymphoblastic Leukemia. *J. Clin. Oncol.* **2007**, *20*, 2063–2069.
23. Orgel, E.; Sposto, R.; Malvar, J.; Seibel, N.L.; Ladas, E.; Gaynon, P.S.; Freyer, D.R. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children’s Oncology Group. *J. Clin. Oncol.* **2014**, *1*, 1331–1337.
24. Orgel, E.; Tucci, J.; Alhushki, W.; Malvar, J.; Sposto, R.; Fu, C.H.; Freyer, D.R.; Abdel-Azim, H.; Mittelman, S.D. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. *Blood* **2014**, *124*, 3932–3938.
25. Hijiya, N.; Panetta, J.C.; Zhou, Y.; Kyzer, E.P.; Howard, S.C.; Jeha, S.; Razzouk, B.I.; Ribeiro, R.C.; Rubnitz, J.E.; Hudson, M.M.; et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. *Blood* **2006**, *108*, 3997–4002.
26. Browne, E.K.; Jeha, S.; Cheng, C.; Relling, M.V.; Campana, D.; Pui, C.H.; Inaba, H. The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. *Blood Cancer J.* **2017**, *7*, e531.
27. Aldhafiri, F.K.; McColl, J.H.; Reilly, J.J. Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia. *J. Pediatr. Hematol. Oncol.* **2014**, *36*, 234–236.
28. Jaime-Pérez, J.C.; Turrubiates-Hernández, G.A.; García-Salas, G.; de la Torre-Salinas, A.M.; Áncer-Rodríguez, P.; Villarreal-Martínez, L.; Gómez-Almaguer, D. The Influence of Nutritional Status at Diagnosis of Childhood B-Cell Acute Lymphoblastic Leukemia on Survival Rates: Data from a Hispanic Cohort. *Nutr. Cancer* **2022**, *74*, 889–895.
29. Suzuki, D.; Kobayashi, R.; Sano, H.; Hori, D.; Kobayash, K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: Its clinical significance. *Int. J. Hematol.* **2018**, *107*, 486–489.
30. Tah, P.C.; Nik Shanita, S.; Pohm, B.K. Nutritional status among pediatric cancer patients: A comparison between hematological malignancies and solid tumors. *J. Spec. Pediatr. Nurs.* **2012**, *17*, 301–311.
31. Yoruk, M.A.; Durakbasa, C.U.; Timur, C.; Sahin, S.S.; Taskin, E.C. Assessment of Nutritional Status and Malnutrition Risk at Diagnosis and Over a 6-Month Treatment Period in Pediatric Oncology Patients with Hematologic Malignancies and Solid Tumors. *J. Pediatr. Hematol. Oncol.* **2018**, *41*, e308–e321.
32. Viani, K.; Barr, R.D.; Filho, V.O.; Ladas, E.J. Nutritional status at diagnosis among children with cancer referred to a nutritional service in Brazil. *Hematol. Transfus. Cell Ther.* **2021**, *43*, 389–395.
33. Garófalo, A.; Lopez, F.A.; Petrilli, A.S. High prevalence of malnutrition among patients with solid non-hematological tumors as found by using skinfold and circumference measurements. *Sao Paulo Med. J.* **2005**, *277*–281.
34. Dos Lemos, P.S.M.; de Oliveira, F.L.C.; Caran, E.M.M. Nutritional Status of Children and Adolescents at Diagnosis of Hematological and Solid Malignancies. *Revista Brasileira de Hematologia e Hemoterapia* **2014**, *36*, 420–423.
35. Radhakrishnan, V.; Ganesan, P.; Rajendranath, R.; Ganesan, T.S.; Sagar, T.G. Nutritional Profile of Pediatric Cancer Patients at Cancer Institute, Chennai. *Indian J. Cancer* **2015**, *52*, 207.
36. Joffe, L.; Dwyer, S.; Glade, B.J.L.; Frazier, A.L.; Ladas, E.J. Nutritional status and clinical outcomes in pediatric patients with solid tumors: A systematic review of the literature. *Semin. Oncol.* **2019**, *46*, 48–56.
37. Goldstein, G.; Shemesh, E.; Frenkel, T.; Jacobson, J.M.; Toren, A. Abnormal body mass index at diagnosis in patients with Ewing sarcoma is associated with inferior tumor necrosis. *Pediatr. Blood Cancer* **2015**, *62*, 1892–1896.
38. Sharib, J.M.; Cyrus, J.; Horvai, A.; Gray, H.F.K.; Neuhaus, J.; Matthay, K.K.; Goldsby, R.; Marina, N.; DuBois, S.G. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. *Pediatr. Blood Cancer* **2012**, *59*, 611–616.
39. Altaf, S.; Enders, F.; Jeavons, E.; Krailo, M.; Barkauskas, D.A.; Meyers, P.; Arndt, C. High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: A report from the Children’s Oncology Group. *Pediatr. Blood Cancer* **2013**, *60*, 2042–2046.
40. Hingorani, P.; Seidel, K.; Krailo, M.; Mascarenhas, L.; Meyers, P.; Marina, N.; Conrad, E.U.; Hawkins, D.S. Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children’s Oncology Group. *Pediatr. Blood Cancer* **2011**, *57*, 939–942.
41. Tenardi, R.D.; Frühwald, M.C.; Jürgens, H.; Herttroijs, D.; Bauer, J. Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy. *Pediatr. Blood Cancer* **2012**, *59*, 621–626.

42. Burke, M.E.; Lyden, E.R.; Meza, J.L.; Ladas, E.J.; Dasgupta, R.; Wiegner, E.A.; Arndt, C.A. Does body mass index at diagnosis or weight change during therapy predict toxicity or survival in intermediate risk rhabdomyosarcoma? A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. *Pediatr. Blood Cancer* **2013**, *60*, 748–753.
43. Lifson, L.F.; Hadley, G.P.; Wiles, N.L.; Pillay, K. Nutritional status of children with Wilms' tumour on admission to a South African hospital and its influence on outcome. *Pediatr. Blood Cancer* **2017**, *64*, e26382.
44. Fernandez, C.V.; Anderson, J.; Breslow, N.E.; Dome, J.S.; Grundy, P.E.; Perlman, E.J.; Green, D.M. Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group. *Pediatr. Blood Cancer* **2009**, *52*, 254–258.
45. Small, A.G.; Thwe, L.M.; Byrne, J.A.; Lau, L.; Chan, A.; Craig, M.E.; Cowell, C.T.; Garnett, S.P. Neuroblastoma, body mass index, and survival: A retrospective analysis. *Medicine* **2015**, *94*, e713.
46. Aarnivala, H.; Pokka, T.; Soininen, R.; Möttönen, M.; Harila-Saari, A.; Niinimäki, R. Trends in age- and sex-adjusted body mass index and the prevalence of malnutrition in children with cancer over 42 months after diagnosis: A single-center cohort study. *Eur. J. Pediatr.* **2020**, *179*, 91–98.
47. Tazi, I.; Hidane, Z.; Zafad, S.; Harif, M.; Benchekroun, S.; Ribeiro, R. Nutritional status at diagnosis of children with malignancies in Casablanca. *Pediatr. Blood Cancer* **2008**, *51*, 495–498.
48. Joffe, L.; Shen, W.; Shadid, G.; Jin, Z.; Ladas, E.J. Skeletal muscle and adipose tissue changes in the first phase of treatment of pediatric solid tumors. *Cancer Med.* **2021**, *10*, 15–22.
49. Tsutsumi, R.C.; Speriđão, P.G.L. Children with brain tumors: A study of nutritional status on hospital admission. *Semina Ciências Biológicas e da Saúde* **2021**, *42*, 51.
50. Musiol, K.; Sobol, G.; Mizia-Malarz, A.; Wos, H. Leptin concentration and nutritional status in the course of treatment in children with brain tumours—Preliminary report. *Childs Nerv. Syst.* **2014**, *30*, 131–136.
51. Barr, R.D.; Ladas, E.J. The role of nutrition in pediatric oncology. *Expert Rev. Anticancer Ther.* **2020**, *20*, 109–116.
52. Marcucci, G.; Beltrami, G.; Tamburini, A.; Body, J.J.; Confavreux, C.B.; Hadji, P.; Holzer, G.; Kendler, D.; Napoli, N.; Pierroz, D.D.; et al. Bone health in childhood cancer: Review of the literature and recommendations for the management of bone health in childhood cancer survivors. *Ann. Oncol.* **2019**, *30*, 908–920.
53. Tillmann, V.; Darlington, A.S.; Eiser, C.; Bishop, N.J.; Davies, H.A. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. *J. Bone Miner. Res.* **2002**, *17*, 1073–1080.
54. Arikoski, P.; Komulainen, J.; Riikonen, P.; Voutilainen, R.; Knip, M.; Kröger, H. Alterations in Bone Turnover and Impaired Development of Bone Mineral Density in Newly Diagnosed Children with Cancer: A 1 Year Prospective Study. *J. Clin. Endocrinol. Metab.* **1999**, *84*, 3174–3181.
55. Rohani, F.; Arjmandi, R.; Bahoush, S.; Ahmad, M. Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia. *Asian Pac. J. Cancer Prev.* **2017**, *18*, 535–540.
56. Cummings, E.A.; Ma, J.; Fernandez, C.V.; Halton, J.; Alos, N.; Miettunen, P.M.; Jaemko, J.L.; Ho, J.; Shenouda, N.; Matzinger, M.A.; et al. Canadian STOPP Consortium (National Pediatric Bone Health Working Group). Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 3408–3417.
57. Alos, N.; Grant, R.M.; Ramsay, T.; Halton, J.; Cummings, E.A.; Miettunen, P.M.; Abish, S.; Atkinson, S.; Barr, R.; Cabral, D.A.; et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. *J. Clin. Oncol.* **2012**, *30*, 2760–2767.
58. Halton, J.; Gaboury, I.; Grant, R.; Alos, N.; Cummings, E.A.; Matzinger, M.; Shenouda, N.; Lentle, B.; Abish, S.; Atkinson, S.; et al. Canadian STOPP Consortium. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: Results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. *J. Bone Miner. Res.* **2009**, *24*, 1326–1334.
59. Rayar, M.S.; Nayiager, T.; Webber, C.E.; Barr, R.D.; Athale, U.H. Predictors of bony morbidity in children with acute lymphoblastic leukemia. *Pediatr. Blood Cancer* **2012**, *15*, 77–82.
60. Nysom, K.; Holm, K.; Michaelsen, K.F.; Hertz, H.; Jacobsen, N.; Müller, J.; Mølgaard, C. Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. *Bone Marrow Transplant.* **2000**, *2*, 191–196.
61. Pirker-Frühau, U.M.; Friesenbichler, J.; Urban, E.C.; Obermayer-Pietsch, B.; Leithner, A. Osteoporosis in children and young adults: A late effect after chemotherapy for bone sarcoma. *Clin. Orthop. Relat. Res.* **2012**, *10*, 2874–2885.
62. Lim, J.S.; Kim, D.H.; Lee, J.A.; Kim, D.H.; Cho, J.; Cho, W.H.; Lee, S.Y.; Jeon, D.G. Young age at diagnosis, male sex, and decreased lean mass are risk factors of osteoporosis in long-term survivors of osteosarcoma. *J. Pediatr. Hematol. Oncol.* **2013**, *1*, 54–60.
63. Remes, T.M.; Arikoski, P.M.; Lähteenmäki, P.M.; Arola, M.O.; Pokka, T.M.; Riikonen, V.P.; Sirkiä, K.H.; Rantala, H.M.J.; Harila-Saari, A.H.; Ojaniemi, M.K. Bone mineral density is compromised in very long-term survivors of irradiated childhood brain tumor. *Acta Oncol.* **2018**, *57*, 665–674.
64. Utriainen, P.; Vatanen, A.; Toiviainen-Salo, S.; Saarinen-Pihkala, U.; Mäkitie, O.; Jahnukainen, K. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue. *Bone Marrow Transplant.* **2017**, *52*, 711–716.
65. Donmez, A.D.; Isik, P.; Cetinkaya, S.; Yarali, N. Bone Loss in Pediatric Survivors of Acute Lymphoblastic Leukemia. *Eurasian J. Med.* **2019**, *51*, 38–41.

66. Schündeln, M.M.; Hauffa, P.K.; Munteanu, M.; Kiewert, C.; Unger, N.; Bauer, J.J.; Hauffa, B.P.; Grasmann, C. Prevalence of Osteopathologies in Children and Adolescents After Diagnosis of Acute Lymphoblastic Leukemia. *Front. Pediatr.* **2020**, *8*, 509.
67. Ahn, J.H.; Cho, W.H.; Lee, J.A.; Kim, D.H.; Seo, J.H.; Lim, J.S. Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. *Ann. Pediatr. Endocrinol. Metab.* **2015**, *3*, 150–154.
68. Holzer, G.; Krepler, P.; Koschat, M.A.; Grampp, S.; Dominkus, M.; Kotz, R. Bone mineral density in long-term survivors of highly malignant osteosarcoma. *J. Bone Jt. Surg. Br. Vol.* **2003**, *85*, 231–237.
69. Perry, B.; Wang, Y. Appetite regulation and weight control: The role of gut hormones. *Nutr. Diabetes* **2012**, *2*, e26.
70. Woodward, O.R.M.; Gribble, F.M.; Reimann, F.; Lewis, J.E. Gut peptide regulation of food intake—Evidence for the modulation of hedonic feeding. *J. Physiol.* **2022**, *600*, 1053–1078.
71. Hariyanto, T.I.; Kurniawan, A. Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. *Cancer Treat. Res. Commun.* **2021**, *27*, 100336.
72. Minor, R.K.; Chang, J.W.; de Cabo, R. Hungry for life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction. *Mol. Cell. Endocrinol.* **2009**, *299*, 79–88.
73. Rios, M. BDNF and the central control of feeding: Accidental bystander or essential player? *Trends Neurosci.* **2013**, *36*, 83–90.
74. Austin, J.; Marks, D. Hormonal regulators of appetite. *Int. J. Pediatr. Endocrinol.* **2009**, *2009*, 141753.
75. Camilleri, M. Peripheral mechanisms in appetite regulation. *Gastroenterology* **2015**, *148*, 1219–1233.
76. Suzuki, K.; Simpson, K.A.; Minnion, J.S.; Shillito, J.C.; Bloom, S.R. The role of gut hormones and the hypothalamus in appetite regulation. *Endocr. J.* **2010**, *57*, 359–372.
77. Date, Y.; Kojima, M.; Hosoda, H.; Sawaguchi, A.; Mondal, M.S.; Suganuma, T.; Matsukura, S.; Kangawa, K.; Nakazato, M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. *Endocrinology* **2000**, *141*, 4255–4261.
78. Sovetkina, A.; Nadir, R.; Fung, J.N.M.; Nadjarpour, A.; Beddoe, B. The Physiological Role of Ghrelin in the Regulation of Energy and Glucose Homeostasis. *Cureus* **2020**, *12*, e7941.
79. Davis, M.P.; Dreicer, R.; Walsh, D.; Lagman, R.; LeGrand, S.B. Appetite and cancer-associated anorexia: A review. *J. Clin. Oncol.* **2004**, *22*, 1510–1517.
80. Wolf, I.; Sadetzki, S.; Kanety, H.; Kundel, Y.; Pariente, C.; Epstein, N.; Oberman, B.; Catane, R.; Kaufman, B.; Shimon, I. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. *Cancer* **2006**, *106*, 966–973.
81. Kerem, M.; Ferahkose, Z.; Yilmaz, U.T.; Pasaoglu, H.; Ofluoglu, E.; Bedirli, A.; Salman, B.; Sahin, T.T.; Akin, M. Adipokines and ghrelin in gastric cancer cachexia. *World J Gastroenterol.* **2008**, *14*, 3633–3641.
82. Salehi, M.; Purnell, J.Q. The Role of Glucagon-Like Peptide-1 in Energy Homeostasis. *Metab. Syndr. Relat. Disord.* **2019**, *17*, 183–191.
83. Price, S.L.; Bloom, S.R. Protein PYY and its role in metabolism. *Front. Horm. Res.* **2014**, *42*, 147–154.
84. Little, T.J.; Horowitz, M.; Feinle-Bisset, C. Role of cholecystokinin in appetite control and body weight regulation. *Obes. Rev.* **2005**, *6*, 297–306.
85. Rehfeld, J.F. Cholecystokinin-From Local Gut Hormone to Ubiquitous Messenger. *Front. Endocrinol.* **2017**, *8*, 47.
86. Czogała, W.; Strojny, W.; Schab, M.; Grabowska, A.; Miklusiak, K.; Kowalczyk, W.; Łazarczyk, A.; Tomasik, P.; Skoczzeń, S. FTO and PLAG1 Genes Expression and FTO Methylation Predict Changes in Circulating Levels of Adipokines and Gastrointestinal Peptides in Children. *Nutrients* **2021**, *13*, 3585.
87. Suzuki, H.; Asakawa, A.; Amitani, H.; Nakamura, N.; Inui, A. Cancer cachexia—Pathophysiology and management. *J. Gastroenterol.* **2013**, *48*, 574–594.
88. Ezeoke, C.C.; Morley, J.E. Pathophysiology of anorexia in the cancer cachexia syndrome. *J. Cachexia Sarcopenia Muscle* **2015**, *6*, 287–302.
89. Skipworth, R.J.; Stewart, G.D.; Dejong, C.H.; Preston, T.; Fearon, K.C. Pathophysiology of cancer cachexia: Much more than host-tumour interaction? *Clin. Nutr.* **2007**, *26*, 667–676.
90. Fayh, A.P.T.; de Lima Bezerra, A.D.; Friedman, R. Appetite hormones in children and adolescents with cancer: A systematic review of observational studies. *Nutrición Hospitalaria* **2018**, *35*, 201–210.
91. Park, S.H.; Jung, M.H.; Chung, N.G.; Suh, B.K.; Lee, B.C. Serum ghrelin and leptin concentrations in children with cancer: Comparisons with normal children. *Korean J. Pediatr.* **2007**, *50*, 90511.
92. Argyrou, C.; Hatziagapiou, K.; Theodorakidou, M.; Nikola, O.A.; Vlahopoulos, S.; Lambrou, G.I. The role of adiponectin, LEP-TIN, and ghrelin in the progress and prognosis of childhood acute lymphoblastic leukemia. *Leuk. Lymphoma* **2019**, *60*, 2158–2169.
93. Gomes, C.C.; Silva, C.C.G.D.; Nascimento, P.R.P.D.; Lemos, T.M.A.M.; Marcadenti, A.; Markoski, M.M.; Fayh, A.P.T. Nutritional status and appetite-regulating hormones in early treatment of acute lymphoblastic leukemia among children and adolescents: A cohort study. *Sao Paulo Med. J.* **2020**, *138*, 118–125.
94. Barbosa-Cortés, L.; Klunder-Klunder, M.; López-Alarcón, M.; Márquez, H.R.; López-Aguilar, E.; Tapia-Marcial, A. Nutritional status and cytokine concentration during chemotherapy in Mexican children: A longitudinal analysis. *Nutrition* **2019**, *57*, 46–51.
95. Skoczzeń, S.; Rej, M.; Kwiecińska, K.; Pietrys, D.; Tomasik, P.J.; Wójcik, M.; Strojny, W.; Dłużniewska, A.; Klimasz, K.; Fijorek, K.; et al. Gastrointestinal peptides in children before and after hematopoietic stem cell transplantation. *BMC Cancer* **2020**, *20*, 306.
96. Watkins, B.A. Diet, endocannabinoids, and health. *Nutr. Res.* **2019**, *70*, 32–39.

97. Iannotti, F.A.; Di Marzo, V. The gut microbiome, endocannabinoids and metabolic disorders. *J. Endocrinol.* **2021**, *248*, R83–R97.
98. Rutkowska, M.; Jamonit, J. Involvement of the Cannabinoid System in the Regulation of Food Intake. *Adv. Clin. Exp. Med.* **2005**, *14*, 1011–1017.
99. Fride, E.; Foxx, A.; Rosenberg, E.; Faigenboim, M.; Cohen, V.; Barda, L.; Blau, H.; Mechoulam, R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a “CB3” receptor. *Eur. J. Pharmacol.* **2003**, *461*, 27–34.
100. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **1992**, *258*, 1946–1949.
101. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem. Pharmacol.* **1995**, *50*, 83–90.
102. Horn, H.; Böhme, B.; Dietrich, L.; Koch, M. Endocannabinoids in Body Weight Control. *Pharmaceuticals* **2018**, *11*, 55.
103. Rahaman, O.; Ganguly, D. Endocannabinoids in immune regulation and immunopathologies. *Immunology* **2021**, *164*, 242–252.
104. Meccariello, R.; Santoro, A.; D’Angelo, S.; Morrone, R.; Fasano, S.; Viggiano, A.; Pierantoni, R. The Epigenetics of the Endocannabinoid System. *Int. J. Mol. Sci.* **2020**, *21*, 1113.
105. Zou, S.; Kumar, U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. *Int. J. Mol. Sci.* **2018**, *19*, 833.
106. Tarragon, E.; Moreno, J.J. Cannabinoids, Chemical Senses, and Regulation of Feeding Behavior. *Chem. Senses* **2019**, *44*, 73–89.
107. Brunt, T.M.; Bossong, M.G. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. *Eur. J. Neurosci.* **2022**, *55*, 909–921.
108. Schulz, P.; Hryhorowicz, S.; Rychter, A.M.; Zawada, A.; Słomski, R.; Dobrowolska, A.; Krela-Kaźmierczak, I. What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity? *Nutrients* **2021**, *13*, 373.
109. Blankman, J.L.; Cravatt, B.F. Chemical probes of endocannabinoid metabolism. *Pharmacol. Rev.* **2013**, *65*, 849–871.
110. Borowska, M.; Czarnywojtek, A.; Sawicka-Gutaj, N.; Woliński, K.; Płazińska, M.T.; Mikołajczak, P.; Ruchała, M. The effects of cannabinoids on the endocrine system. *Endokrynol. Pol.* **2018**, *69*, 705–719.
111. Andradas, C.; Truong, A.; Byrne, J.; Endersby, R. The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology. *Cancers* **2021**, *13*, 157.
112. Izzo, A.A.; Sharkey, K.A. Cannabinoids and the gut: New developments and emerging concepts. *Pharmacol. Ther.* **2010**, *126*, 21–38.
113. Ravinet, T.C.; Delgorge, C.; Menet, C.; Arnone, M.; Soubrié, P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. *Int. J. Obes. Relat. Metab. Disord.* **2004**, *28*, 640–648.
114. Cardinal, P.; Bellocchio, L.; Clark, S.; Cannich, A.; Klugmann, M.; Lutz, B.; Marsicano, G.; Cota, D. Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice. *Endocrinology* **2012**, *153*, 4136–4143.
115. Abdalla, M.M. Central and peripheral control of food intake. *Endocr. Regul.* **2017**, *51*, 52–70.
116. Gatta-Cherifi, B.; Cota, D. New insights on the role of the endocannabinoid system in the regulation of energy balance. *Int. J. Obes.* **2016**, *40*, 210–219.
117. Kola, B.; Farkas, I.; Christ-Crain, M.; Wittmann, G.; Lolli, F.; Amin, F.; Harvey-White, J.; Liposits, Z.; Kunos, G.; Grossman, A.B.; et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. *PLoS ONE* **2008**, *3*, e1797.
118. Di Marzo, V.; Goparaju, S.K.; Wang, L.; Liu, J.; Bátkai, S.; Járjai, Z.; Fezza, F.; Miura, G.I.; Palmiter, R.D.; Sugiura, T.; et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature* **2001**, *410*, 822–825.
119. Komorowski, J.; Stepień, H. The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans. *Postepy Higieny i Medycyny Doswiadczalnej* **2007**, *61*, 99–105.
120. Tagliamonte, S.; Laiola, M.; Ferracane, R.; Vitale, M.; Gallo, M.A.; Meslier, V.; Pons, N.; Ercolini, D.; Vitaglione, P.; Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: Possible links with gut microbiome, insulin resistance and inflammation. *Eur. J. Nutr.* **2021**, *60*, 3703–3716.
121. Tagliamonte, S.; Gill, C.I.R.; Pourshahidi, L.K.; Slevin, M.M.; Price, R.K.; Ferracane, R.; Lawther, R.; O’Connor, G.; Vitaglione, P. Endocannabinoids, endocannabinoid-like molecules and their precursors in human small intestinal lumen and plasma: Does diet affect them? *Eur. J. Nutr.* **2021**, *60*, 2203–2215.
122. Argenziano, M.; Tortora, C.; Bellini, G.; Di Paola, A.; Punzo, F.; Rossi, F. The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases. *Int. J. Mol. Sci.* **2019**, *20*, 5875.
123. Scott, K.A.; Dalgleish, A.G.; Liu, W.M. Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. *Int. J. Oncol.* **2017**, *51*, 369–377.
124. Liu, W.M.; Scott, K.A.; Shamash, J.; Joel, S.; Powles, T.B. Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. *Leuk. Lymphoma* **2008**, *49*, 1800–1809.
125. Oesch, S.; Walter, D.; Wachtel, M.; Pretre, K.; Salazar, M.; Guzman, M.; Velasco, G.; Schafer, B.W. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. *Mol. Cancer Ther.* **2009**, *8*, 1838–1845.
126. Fisher, T.; Golan, H.; Schiby, G.; PriChen, S.; Smoum, R.; Moshe, I.; Peshes-Yaloz, N.; Castiel, A.; Waldman, D.; Gallily, R.; et al. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. *Curr. Oncol.* **2016**, *23*, S15–S22.

127. Notaro, A.; Sabella, S.; Pellerito, O.; Di Fiore, R.; De Blasio, A.; Vento, R.; Calvaruso, G.; Giuliano, M. Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis. *Int. J. Biol. Sci.* **2014**, *10*, 466–478.
128. Sredni, S.T.; Huang, C.C.; Suzuki, M.; Pundy, T.; Chou, P.; Tomita, T. Spontaneous involution of pediatric low-grade gliomas: High expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system. *Childs Nerv. Syst.* **2016**, *32*, 2061–2067.